JP2023541432A5 - - Google Patents
Info
- Publication number
- JP2023541432A5 JP2023541432A5 JP2023516476A JP2023516476A JP2023541432A5 JP 2023541432 A5 JP2023541432 A5 JP 2023541432A5 JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023516476 A JP2023516476 A JP 2023516476A JP 2023541432 A5 JP2023541432 A5 JP 2023541432A5
- Authority
- JP
- Japan
- Prior art keywords
- medication
- administration
- days
- composition according
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078844P | 2020-09-15 | 2020-09-15 | |
| US63/078,844 | 2020-09-15 | ||
| PCT/JP2021/033855 WO2022059692A1 (en) | 2020-09-15 | 2021-09-15 | Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541432A JP2023541432A (ja) | 2023-10-02 |
| JP2023541432A5 true JP2023541432A5 (cg-RX-API-DMAC7.html) | 2024-08-14 |
| JP7828333B2 JP7828333B2 (ja) | 2026-03-11 |
Family
ID=80776678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516476A Active JP7828333B2 (ja) | 2020-09-15 | 2021-09-15 | リボヌクレオチドリダクターゼ阻害剤を用いるリボヌクレオチドリダクターゼ関連疾患の治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230390251A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4213842B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7828333B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230067647A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021345171A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3070493T3 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202227060A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022059692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011121453A2 (en) * | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| US10889555B2 (en) * | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| TWI748142B (zh) * | 2017-11-29 | 2021-12-01 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑 |
-
2021
- 2021-09-15 KR KR1020237012413A patent/KR20230067647A/ko not_active Withdrawn
- 2021-09-15 AU AU2021345171A patent/AU2021345171A1/en active Pending
- 2021-09-15 US US18/026,515 patent/US20230390251A1/en active Pending
- 2021-09-15 TW TW110134368A patent/TW202227060A/zh unknown
- 2021-09-15 WO PCT/JP2021/033855 patent/WO2022059692A1/en not_active Ceased
- 2021-09-15 JP JP2023516476A patent/JP7828333B2/ja active Active
- 2021-09-15 ES ES21869378T patent/ES3070493T3/es active Active
- 2021-09-15 EP EP21869378.6A patent/EP4213842B1/en active Active